WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2016 Healthcare Conference on June 8, 2016 at 11:00 a.m. Eastern Time.
The Company will present further data from the Phase IIb trial with MIN-101 in schizophrenia and the Phase IIa trial with MIN-117 in major depressive disorder (MDD). Top line results from these studies were announced on May 26, 2016. Additional information from recent MIN-202 studies carried out in insomnia and MDD will also be presented. Top line results from both of these studies were announced earlier this year. MIN-202 is under joint development with Janssen Pharmaceutica NV.
The presentation will be web cast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, which has successfully completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has successfully completed Phase IIa and Phase Ib clinical trials in insomnia and MDD, respectively; MIN-117, which has successfully completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.